AbbVie Inc. vs BP plc: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and BP plc across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating BP plc, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and BP plc is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $189.3B for BP plc, while their respective market capitalizations stand at $451.5B and $80.0B. AbbVie Inc. is headquartered in United States and BP plc operates from United Kingdom, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

BP plc: BP combines a long operating history with a current strategy shaped by FY2025 financial results, leadership priorities, and competitive pressure.

AbbVie Inc. and BP plc pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and BP plc.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

BP plc business model: BP makes money through oil and gas production, LNG and power trading, refining, retail fuels, Castrol lubricants, and selective low-carbon investments. Its model depends on disciplined capital allocation, durable customer or channel relationships, and execution inside markets where scale and trust matter.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of BP plc.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

BP plc competitive advantage: The balance sheet survived a catastrophe that would have ended most companies, and the institution continues to function at scale. BP faces a constellation of challenges that are simultaneously financial, operational, reputational, and existential — and that interact with each other in ways that make navigation exceptionally difficult even for a company of its scale and experience. The most fundamental advantage is BP's portfolio of world-class upstream assets. BP's integrated supply and trading capability is a second major competitive advantage that is widely recognized within the industry but less visible to outside observers. The Castrol brand, operated within the Customers & Products segment, represents a third distinct competitive advantage.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and BP plc each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

BP plc growth strategy: BP is trying to simplify its portfolio, reduce net debt, sharpen upstream and trading returns, and rebuild investor confidence after several years of strategy and leadership resets.

A closer look at the financial trajectory of AbbVie Inc. and BP plc rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

BP plc: BP reported $189.3B in FY2025 revenue and $55M in net income/profit attributable to the company or shareholders. In 2025 BP reported $189.335B in sales and other operating revenues, $55M of profit attributable to BP shareholders, and $7.485B of underlying replacement-cost profit.